NCT00377299View on ClinicalTrials.gov

A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Amphetamine AbuseAmphetamine DependenceBipolar DisorderMajor Depressive Disorder
Interventions
DRUG

Citicoline

Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.

DRUG

Placebo

Placebo matching active medication in all other physical aspects

Trial Locations (1)

75390

Psychoneuroendocrine Research Program, Dallas

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

University of Texas Southwestern Medical Center

OTHER

NCT00377299 - A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence | Biotech Hunter | Biotech Hunter